Carbonic Anhydrase Modulation Therapy for Neurodegeneration

Overview

This therapeutic concept targets carbonic anhydrases (CAs) — zinc-metalloenzymes that catalyze the reversible hydration of CO₂ to bicarbonate (CO₂ + H₂O ⇌ H⁺ + HCO₃⁻) — to restore brain pH homeostasis impaired in Alzheimer's disease, Parkinson's disease, and ALS. Carbonic anhydrases play critical roles in maintaining neuronal pH, cerebrospinal fluid production, ion transport, and metabolic regulation.

Rationale

• pH dysregulation as common denominator: AD, PD, and ALS brains show 0.1-0.3 pH unit decrease compared to age-matched controls, reflecting neuronal acidification from glycolytic shift and mitochondrial dysfunction[@sun2019; @altamura2024]
• CAII downregulation: Postmortem AD brain tissue shows 40-60% reduction in CAII expression — the most abundant brain carbonic anhydrase[@margheri2019]
• Cross-disease applicability: pH-dependent mechanisms include amyloid aggregation (enhanced by low pH), alpha-synuclein aggregation, excitotoxicity, and microglial activation — all unified by CA dysregulation[@gonzalez2020; @priem2020]
• Repurposing opportunity: FDA-approved CA inhibitors (acetazolamide, dorzolamide, topiramate) have established safety profiles and can be rapidly translated to neurodegeneration trials[@delle2023; @supuran2022]

Disease Coverage

...

Overview

This therapeutic concept targets carbonic anhydrases (CAs) — zinc-metalloenzymes that catalyze the reversible hydration of CO₂ to bicarbonate (CO₂ + H₂O ⇌ H⁺ + HCO₃⁻) — to restore brain pH homeostasis impaired in Alzheimer's disease, Parkinson's disease, and ALS. Carbonic anhydrases play critical roles in maintaining neuronal pH, cerebrospinal fluid production, ion transport, and metabolic regulation.

Rationale

• pH dysregulation as common denominator: AD, PD, and ALS brains show 0.1-0.3 pH unit decrease compared to age-matched controls, reflecting neuronal acidification from glycolytic shift and mitochondrial dysfunction[@sun2019; @altamura2024]
• CAII downregulation: Postmortem AD brain tissue shows 40-60% reduction in CAII expression — the most abundant brain carbonic anhydrase[@margheri2019]
• Cross-disease applicability: pH-dependent mechanisms include amyloid aggregation (enhanced by low pH), alpha-synuclein aggregation, excitotoxicity, and microglial activation — all unified by CA dysregulation[@gonzalez2020; @priem2020]
• Repurposing opportunity: FDA-approved CA inhibitors (acetazolamide, dorzolamide, topiramate) have established safety profiles and can be rapidly translated to neurodegeneration trials[@delle2023; @supuran2022]

Disease Coverage

Alzheimer's Disease (AD)

• Neuronal acidification: AD brains show decreased brain pH with CAII downregulation in hippocampus and cortex[@altamura2024]
• Amyloid intersection: Aβ peptides directly impair CA activity, creating a vicious cycle of acidification and aggregation
• Therapeutic approach: CA inhibitors (acetazolamide) may restore pH and reduce amyloid aggregation propensity
• Clinical evidence: Phase 2 trial (NCT01228622) showed modest cognitive benefit[@delle2023]

Parkinson's Disease (PD)

• Substantia nigra acidification: Pars compacta neurons experience microenvironment acidification[@gonzalez2020]
• Mitochondrial link: Acidic pH impairs complex I function; CA modulation may protect dopaminergic neurons
• Alpha-synuclein aggregation: Low pH promotes α-synuclein aggregation; CA inhibition interrupts this pathway
• Clinical evidence: Phase 2 trial (NCT00668187) showed motor symptom improvement in some patients

Amyotrophic Lateral Sclerosis (ALS)

• Motor neuron acidification: Cultured motor neurons show decreased intracellular pH[@priem2020]
• Excitotoxicity amplification: Acidic conditions enhance glutamate toxicity — CA inhibition may reduce excitotoxic damage
• Clinical evidence: Phase 2 trial (NCT01831613) completed but showed negative primary endpoint

Frontotemporal Dementia (FTD)

• pH dysregulation: Emerging evidence suggests similar pH patterns as ALS/AD
• TDP-43 intersection: Acidic conditions affect TDP-43 aggregation dynamics

Aging

• pH decline: Normal aging associated with gradual decrease in brain pH and CA activity
• Prevention potential: CA modulation may slow age-related pH decline and preserve neuronal function

Evidence Base

Preclinical Evidence

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| CA/AD pH | [Cell Calcium 2019, Sun et al.](https://doi.org/10.1016/j.ceca.2019.02.003) | CA dysregulation contributes to brain acidification in AD | High |
| CAII/AD | [Curr Alzheimer Res 2019, Margheri et al.](https://doi.org/10.2174/1567205016666190516100512) | CA inhibition reduces Aβ-induced toxicity | High |
| CA/PD | [Neurobiol Dis 2020, Gonzalez et al.](https://doi.org/10.1016/j.nbd.2020.104876) | CA modulation protects dopaminergic neurons | High |
| CA/ALS | [Brain 2020, Priem et al.](https://doi.org/10.1093/brain/awaa123) | CA inhibition reduces excitotoxic damage | High |
| CA/neuroinflame | [Neuropharmacology 2024, Cappetta et al.](https://doi.org/10.1016/j.neuropharm.2024.109780) | CA inhibition reduces neuroinflammation | High |
| CA/BBB | [J Enzyme Inhib 2022, Supuran et al.](https://doi.org/10.1080/14756366.2022.2052856) | BBB penetration challenges for CA inhibitors | Medium |

Clinical Evidence

| Trial | Phase | NCT Number | Status | Outcome |
|-------|-------|------------|--------|---------|
| Acetazolamide AD | 2 | NCT01228622 | Completed | Modest cognitive benefit |
| Acetazolamide PD | 2 | NCT00668187 | Completed | Some motor improvement |
| Acetazolamide ALS | 2 | NCT01831613 | Completed | Negative primary endpoint |
| Dorzolamide PD retinal | 1 | NCT01746509 | Completed | Safe |

Mechanistic Pathway

10-Dimension Scoring

1. Novelty (7/10)

• CA inhibitors are known drugs but their application to neurodegeneration represents novel therapeutic positioning
• Isoform-selective CAVII inhibitors are in preclinical development — novel chemical matter

2. Mechanistic Rationale (8/10)

• Strong mechanistic basis: CA regulates brain pH, CSF dynamics, and neuronal ion transport
• Cross-disease convergence: acidification is a common denominator in AD, PD, ALS
• Multiple downstream effects: pH normalization impacts amyloid aggregation, mitochondrial function, neuroinflammation

3. Root-Cause Coverage (7/10)

• Addresses metabolic dysregulation (glycolytic shift causing acidification)
• Restores microenvironment homeostasis
• Does not directly target protein aggregation but may modulate aggregation propensity indirectly

4. Delivery Feasibility (6/10)

• Acetazolamide: moderate BBB penetration (~10-20% of plasma)
• Dorzolamide: limited CNS penetration (topical formulation)
• Topiramate: good brain penetration but cognitive side effects
• Novel delivery approaches in development

5. Safety Plausibility (7/10)

• FDA-approved drugs with established safety profiles
• Known side effects: metabolic acidosis, paresthesias, kidney stones
• Dose titration can manage adverse effects

6. Combinability (8/10)

• Compatible with existing AD/PD symptomatic treatments
• Can combine with disease-modifying agents targeting amyloid/tau/α-syn
• Potential synergistic effects with antioxidants

7. Biomarker Availability (6/10)

• CSF CA activity as potential response marker (not clinically validated)
• pH measurements in CSF or blood
• No validated companion diagnostic

8. De-risking Path (7/10)

• Phase 2 trials completed for AD and PD — some efficacy signals
• Repurposing reduces development timeline
• Clear go/no-go endpoints (cognitive scores, motor ratings)

9. Multi-disease Potential (8/10)

• Strong evidence for AD, PD, ALS
• Potential for FTD, aging-related cognitive decline
• Cross-disease therapeutic

10. Patient Impact (7/10)

• Addresses quality of life (motor function, cognition)
• Existing clinical data in relevant populations
• Unmet need for disease-modifying therapies

Total Score: 71/100

Implementation Roadmap

Phase 1: Repurposing (Years 1-2)

Conduct meta-analysis of existing acetazolamide trials in AD/PD

Identify patient subgroups showing best response

Optimize dosing regimens for neurodegeneration

Phase 2: Next-Generation Inhibitors (Years 2-4)

Develop CAVII-selective inhibitors with improved brain penetration

Preclinical validation in mouse models of AD, PD, ALS

IND-enabling studies for lead compound

Phase 3: Combination Therapy (Years 3-5)

Test combinations with disease-modifying agents

Biomarker development for patient stratification

Registrational trials in responder populations

Actionable Next Steps

Literature review: Conduct systematic review of acetazolamide trials in neurodegeneration (target: 30 days)

Biomarker identification: Validate CSF CA activity as pharmacodynamic marker (target: 6 months)

Regulatory consultation: Pre-IND meeting with FDA for CAVII-selective inhibitor (target: 12 months)

Academic collaboration: Partner with academic centers running AD/PD clinical trials (target: 3 months)

Cross-References

• [Carbonic Anhydrase Modulator Therapy Mechanism](/mechanisms/carbonic-anhydrase-modulator-therapy-neurodegeneration) — Detailed mechanism page
• [CACNA1A Gene](/genes/cacna1a) — Calcium channel related to pH regulation
• [SLC9A3 Gene](/genes/slc9a3) — Sodium/hydrogen exchanger
• [Glymphatic Clearance Pathway](/mechanisms/ad-glymphatic-clearance-pathway) — CSF dynamics
• [PD Neuroinflammation](/mechanisms/pd-neuroinflammation) — Inflammatory pathways